Scott L. Friedman

Dr. Scott L. Friedman is the Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, at the Icahn School of Medicine at Mount Sinai. Continuously funded by NIH since 1985, he has performed pioneering research into the underlying causes of fibrosis associated with chronic liver disease. Dr. Friedman was among the first to isolate and characterize the hepatic stellate cell, which is the primary fibrogenic cell in liver. His work has helped spawn an entire field that is now realizing its translational and therapeutic potential, with new anti-fibrotic therapies for liver disease reaching clinical trials. His honors include the International Hans Popper Award, a Senior Fulbright Fellowship at the Weizmann Institute, Israel, the EASL International Recognition Award, the AASLD and ALF Distinguished Achievement Awards, and dozens of visiting Professorships worldwide. He has mentored over 90 trainees, almost all of whom have pursued successful academic and/or research careers.